### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

### 1 Completion of multi-dose COVID-19 vaccines and the associated factors among adolescents

### 2 and adults in two urban informal settlements in Nairobi, Kenya

### 3 Authors

- 4 Maurine Ng'oda<sup>1</sup>, Jonathan Izudi<sup>2</sup>, Collins Otieno<sup>1</sup>, Daniel Mwanga<sup>2</sup>, Richard E. Sanya<sup>1</sup>,
- 5 Abdhalah Ziraba<sup>1</sup>

### 6 Affiliations

- <sup>7</sup> <sup>1</sup>Emerging and Re-Emerging Infectious Diseases Unit, African Population and Health Research
- 8 Center, Nairobi, Kenya.
- <sup>9</sup> <sup>2</sup>Data Science and Evaluation, African Population and Health Research Center, Nairobi, Kenya.

10

11

### 12 <u>Corresponding author</u>

- 13 Maurine Ng'oda\*
- 14 African Population and Health Research Center, Nairobi
- 15 Email: <u>mngoda@aphrc.org</u>
- 16 Phone: +254724137389

#### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

#### 17 ABSTRACT

Completion of vaccine doses is essential for robust immunity and long-term protection 18 against specific diseases. This study aimed to investigate factors associated with the completion of 19 20 multi-dose COVID-19 vaccines (MDV) among adolescents and adults in two informal urban settlements in Nairobi, Kenya. We analyzed data from the Kenya Multisite Integrated 21 Serosurveillance (KEMIS) project. We defined completion of MDV as receiving an additional 22 23 COVID-19 vaccine dose between weeks 6 and 8 following the first COVID-19 vaccination shot. 24 We applied the modified Poisson regression model with robust standard errors to determine the factors that were independently associated with the completion of MDV. We analyzed data from 25 26 402 individuals aged 14-90 years and found that the completion rate for MDV was 85.3%. In the 27 adjusted analysis, participants aged ≥60 years (adjusted prevalence risk ratio [aPR] 1.30, 95% 28 confidence interval [CI] 1.05-1.60) and those who recommended the COVID-19 vaccine to others (aPR 1.40, 95% CI 1.00-1.96) were significantly more likely to complete MDV. Individuals aged 29 25-59 years (aPR 1.22, 95% CI 0.99-1.50), those who perceived themselves as being at risk for 30 COVID-19 (aPR 1.09, 95% CI 0.99-1.19), and those who had access to healthcare during the 31 pandemic tended to have a higher completion of MDV. Overall, the MDV completion rate is 32 relatively high, however, public health interventions should endeavor to target those being left 33 34 behind such as younger individuals and those hesitant about vaccination.

35 **KEYWORDS:** Vaccines, COVID-19, multiple doses, informal settings.

#### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

#### 37 BACKGROUND

38	The COVID-19 pandemic posed unprecedented challenges to global public health, with
39	vaccination emerging as one of the most effective tools to mitigate transmission and reduce severe
40	outcomes such as hospitalization and mortality. <sup>1</sup> By August 12, 2024, 13.72 billion doses of
41	COVID-19 vaccine had been administered globally. However, Africa had received the least
42	number of doses (874.76 million), <sup>2</sup> revealing significant gaps in both vaccine access and uptake. <sup>3,4</sup>

In Kenya, the most commonly used COVID-19 vaccines included Oxford/AstraZeneca, 43 Moderna, and Pfizer and each requires multiple doses to ensure complete immunization.<sup>5</sup> The 44 45 completion of multi-dose vaccine regimens is critical for eliciting stronger immunity and longerterm protection against severe COVID-19. The second dose significantly enhances the immune 46 response, boosting the efficacy to over 90% in preventing severe disease.<sup>6</sup> Failure to complete 47 48 multi-dose regimens undermines this protection and potentially leads to vaccine failure, greater risks for infection, and reduced overall effectiveness of immunization programs including 49 increased susceptibility to COVID-19 variants and reduced community-level immunity.<sup>7</sup> 50

Disparities in the completion of multi-dose vaccines for COVID-19 (MDV) exist, 51 particularly in low-income and marginalized populations such as urban informal settlements.<sup>8</sup> 52 53 Urban informal settlements are often characterized by overcrowding, inadequate healthcare infrastructure, and limited access to essential services. In Kenya, an estimated 60% of the residents 54 in Nairobi City reside in informal settlements. The overall COVID-19 vaccine uptake among this 55 population is around 34% <sup>9</sup> but the completion of MDV is understudied. Understanding the 56 completion of MDV is crucial for developing targeted interventions that improve COVID-19 57 vaccine uptake in such settings. We investigated the prevalence of completion of MDV and the 58

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

59 associated factors among adolescents and adults in two large urban informal settlements in

60 Nairobi, Kenya.

61

#### 62 MATERIALS AND METHODS

63 Study setting

Data used in this paper comes from the Kenya Multisite Integrated Serosurveillance 64 65 (KEMIS) for COVID-19 and Other Pathogens Project. The KEMIS Project was jointly implemented by the African Population and Health Research Center (APHRC), the Kenya Medical 66 Research Institute Wellcome Trust Research Programme, and the Centers for Disease Control and 67 68 Prevention (CDC). The project aimed to estimate the sero-prevalence of SARS-CoV-2 antibodies in the general population. It involved serosurveys conducted among residents of Kilifi, Nairobi, 69 70 and Manyatta Health and Demographic Surveillance Systems (HDSS). The details of HDSS have been previously discussed.<sup>9</sup> The analysis in this paper comes from the Nairobi site. The Nairobi 71 72 Urban HDSS (NUHDSS) is established in Nairobi City County, and has consistently tracked a population of approximately 90,000 people each year spread across 30,000 households in two slum 73 areas of Korogocho and Viwandani.<sup>10</sup> 74

### 75 Study design and eligibility

Four cross-sectional sero-surveys were conducted between October 2020 and June 2024 on a random age-stratified sample of 850 NUHDSS residents totaling 3,400 observations. These samples consisted of 50 people from each 5-year age group between 15 and 64 years, 50 people aged 65 and above, and 100 children from each 5-year age group between 0 and 14 years. This

#### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

resulted in 300 participants under 15 years old sufficient to estimate a 1% outcome measure rate 80 81 with a 2% margin of error. For the 15-64 age group, 500 participants were deemed adequate to estimate an outcome rate of 3-5% within a 5% margin of error. The survey excluded individuals 82 with bleeding disorders and other medical contraindications for venipuncture or capillary blood 83 84 sample collection. Data was collected using structured questionnaires and laboratory analysis of 85 blood samples for COVID-19 antibodies. The questionnaire captured sociodemographic 86 information, information on likely exposure to SARS-Cov-2, and clinical information such as 87 COVID-19 symptoms, childhood immunization, death of household members, and vaccination status. Vaccination status was verified using the vaccination certificate or text message 88 confirmation from the national COVID-19 registry. Other information collected included access 89 90 to health services during the pandemic and loss of income during COVID-19.

91

#### 92 Measurements and variables

93 The present study utilized data from the second and third survey rounds of the survey since the first round of the survey took place before the COVID-19 vaccine rollout in the country and 94 the fourth round of the survey did not include key variables that were considered for the current 95 analysis. We considered observations for individuals who were eligible for COVID-19 vaccination 96 and who had received the first dose of MDV, namely AstraZeneca, Moderna, Pfizer, and 97 Sinopharm. We excluded records for the following individuals: those ineligible for the COVID-98 19 vaccine based on age, who never received any COVID-19 vaccination, who never knew the 99 100 vaccine they had received at first vaccination, and those who had missing vaccination information.

#### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

The primary outcome variable of interest was completion of MDV measured as a binary 101 102 outcome and defined as the receipt of an additional dose of a COVID-19 vaccine between weeks 103 6 and 8 following the first dose of an MDV. The independent variables included age measured as 104 the number of years lived and categorized as 14-24, 25-59, and  $\geq 60$  years to respectively denote adolescents and young people, middle-aged persons, and older persons; sex (male vs. female); 105 106 religion measures as None, Muslim, Christians, and Others; education level was measured as 107 none, primary, secondary, and post-secondary; exposure to a suspected COVID-19 case was 108 measured as no, yes, probable, and not reported; access to healthcare during the COVID-19 pandemic was measured on a binary scale as yes or no; and perceived risk of COVID-19 infection 109 110 was measured as no risk vs. at risk. Additionally, we assessed vaccine whether the participants 111 were willing to recommend COVID-19 vaccination to others and whether they had any household member who had died from COVID-19. 112

#### 113 Statistical analysis

We summarized categorical variables as frequencies and proportions. Numerical variables 114 were summarized using the mean and standard deviation as they were normally distributed. The 115 Chi-square test was used to examine differences in MDV completion by the covariates at a 0.15 116 significance level in the bivariate analysis. We used the modified (robust) Poisson regression 117 118 model to determine the factors independently associated with MDV completion adjusting for both clinically and socially relevant variables from the literature, statistically significant variables at the 119 bivariate analysis, and robust standard errors as recommended by Cameron and Trivedi. We report 120 121 both the unadjusted and adjusted prevalence risk ratios (PR) along with the 95% confidence intervals (CIs). Variables with p<0.05 were considered statistically significant in the multivariable 122 123 modified Poisson regression analysis.

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

#### 124

# 125 **Ethical considerations**

126	The KEMIS project obtained ethical approval from the Kenya Medical Research Institute
127	Scientific and Ethics Review Unit (Reference no. KEMRI/SERU/ CGMR-C/203/4085), The
128	National Commission for Science, Technology and Innovation (License no.
129	NACOSTI/P/21/13771), the Oxford Tropical Research Ethics Committee (Reference no. 44–20),
130	and the London School of Hygiene and Tropical Medicine Research Ethics Committee (Reference
131	no. 26950). Written parental/guardian consent was obtained for participants aged <18 years,
132	accompanied by written assent for children aged 13 to 17 years.


133

### 134 **RESULTS**

### 135 Study profile

We considered data from 1,701 participants and excluded 1,295 that did not meet the eligibility criteria. Overall, we analyzed 402 participants of whom 343 (85.0%) completed MDV as shown in Figure 1.

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings



139

140 Figure 1. Study profile based on eligibility criteria.

141

#### 142 General characteristics of the participants

143 We present the general characteristics of the participants in Table 1. Of the 402 participants,

144 262 (65.2%) were from Viwandani study site, 264 (65.7%) were male, 254 (63.2%) were aged

145 25-59 years and the overall mean age was 48.5±15.7 332 (80.1%) participants had no known

146 contact with confirmed/suspected COVID-19 cases, 260 (64.7%) perceived themselves as being

147 at risk for infection, and 361 (89.8%) lacked access to healthcare during the pandemic.

148

149

150

# Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

152			
153			
154			
155			
156			
157			
158			
159			
160			

## 161 Table 1. General characteristics of participants who received multi-dose COVID-19 vaccine

Variables	Level	All (n=402)
Study site	Korogocho	140 (34.8)
	Viwandani	262 (65.2)
Survey rounds	Round 2	172 (42.8)
	Round 3	230 (57.2)
Age group (years)	14-24	43 (10.7)
	25-59	254 (63.2)
	≥60	105 (26.1)
	mean (SD)	48.53 (15.71)
Sex	Female	138 (34.3)
	Male	264 (65.7)
Level of education	None	16 (4.0)
	Primary	169 (42.0)
	Secondary	179 (44.5)
	Post-secondary	38 (9.5)
Religion	None	9 (2.2)
	Muslim	13 (3.2)
	Christians	270 (67.2)
	Others	110 (27.4)
Ever exposed to suspected COVID-19 case	No	332 (80.1)

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

	Yes	36 (9.0)
	Probable	30 (7.5)
	Not reported	14 (3.5)
Had access to healthcare during the COVID-19 pandemic	No	361 (89.8)
	Yes	35 (8.7)
	Not reported	6 (1.5)
Perceived risk of infection with COVID-19	No risk	142 (35.3)
	At risk	260 (64.7)
History of the household member who died of COVID-19	No	370 (92.0)
	Yes	30 (7.5)
	Do not know	2 (0.5)
Would recommend the COVID-19 vaccine to others	No	19 (4.7)
	Yes	383 (95.3)

162

- 163
- 164

### 165 Type and timing of receipt of multi-dose COVID-19 vaccine (MDV)

Table 2 summarizes the types and timing of MDV at the first and second shots. At the first shot, 266 (66.2%) participants received the AstraZeneca vaccine, 61 (15.2%) received Pfizer, 74 (18.4%) received Moderna, and 1 (0.2%) received the Sinopharm vaccine. At the second shot, the number of participants that received the AstraZeneca vaccine dropped to 224 (55.7%), and that for Pfizer and Moderna dropped to 59 (14.7%) and 56 (13.9%) respectively. One participant received Sinopharm at the first and second shots. At the second shot, 59 (14.7%) participants did not return for their COVID-19 vaccine. Overall, 343 (85.3%) participants completed their MDV in this study.

174

175

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

177			
178			
179			
180			
181			
182			

183

184 Table 2. Type and timing of receipt of multi-dose COVID-19 vaccine (MDV)

Variable	Level	Overall (n=402)
COVID-19 vaccine at the first shot	AstraZeneca	266 (66.2)
	Pfizer	61 (15.2)
	Moderna	74 (18.4)
	Sinopharm	1 (0.2)
COVID-19 vaccine at the second shot	AstraZeneca	224 (55.7)
	Pfizer	59 (14.7)
	J & J	1 (0.2)
	Moderna	56 (13.9)
	Sinopharm	1 (0.2)
	Don't know	2 (0.5)
	Never returned	59 (14.7)
Completed multi-dose COVID-19 vaccine (MDV)	No	59 (14.7)
	Yes	343 (85.3)

185

### 186 Completion of MDV by the socio-demographic characteristics and other factors

187 The completion of MDV varied across different sociodemographic characteristics and 188 other influencing factors as shown in Table 3. Completion rates were high across both study sites, 189 with 85.7% in Korogocho and 85.1% in Viwandani (p=0.871). Individuals aged  $\geq 60$  years had the

# Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

190	highest completion rate at 91.4%, while those aged 14-24 had a lower completion rate at 69.8%
191	(p=0.003). The mean age of completers was significantly higher (50.14 years) compared to non-
192	completers (39.17 years, p<0.001). There were no significant differences in completion rates by
193	sex, with males and females completing at rates of 85.6% and 84.8%, respectively (p=0.825).
194	Educational level showed modest differences, with those having no education showing the highest
195	completion rate (93.8%), though this was not statistically significant (p=0.504). Religion was not
196	a significant factor, though Muslims reported a 100% completion rate compared to 86.7% among
197	Christians (p=0.102). The perceived risk of COVID-19 infection was marginally associated with
198	completion, as those perceiving themselves at risk had a higher completion rate (87.7%) compared
199	to those perceiving no risk (81.0%, p=0.069). Finally, willingness to recommend the COVID-19
200	vaccine was significantly associated with completion; 86.4% of those who would recommend the
201	vaccine completed MDV compared to 63.2% among those who would not recommend it
202	(p=0.005).

# Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

- 211
- 212
- 213
- 214
- 215

		Complet		
Variables	Level	No (n=59)	Yes	<b>P-value</b>
			(n=343)	
Study site	Korogocho	20 (14.3)	120 (85.7)	0.871
	Viwandani	39 (14.9)	223 (85.1)	
Survey rounds	Round 2	26 (15.1)	146 (84.9)	0.829
	Round 3	33 (14.3)	197 (85.7)	
Age group (years)	14-24	13 (30.2)	30 (69.8)	0.003
	25-59	37 (14.6)	217 (85.4)	
	≥60	9 (8.6)	96 (91.4)	
	mean (SD)	39.17	50.14	< 0.001
		(15.73)	(15.16)	
Sex	Female	21 (15.2)	117 (84.8)	0.825
	Male	38 (14.4)	226 (85.6)	
Level of education	None	1 (6.3)	15 (93.8)	0.504
	Primary	22 (13.0)	147 (87.0)	
	Secondary	31 (17.3)	148 (82.7)	
	Post-secondary	5 (13.2)	33 (86.8)	
Religion	None	3 (33.3)	6 (66.7)	0.102
	Muslim	0 (0.0)	13 (100.0)	
	Christians	36 (13.3)	234 (86.7)	
	Others	20 (18.2)	90 (81.8)	
Ever exposed to suspected COVID-19 case	No	44 (13.7)	278 (86.3)	0.660
	Yes	7 (19.4)	29 (80.6)	
<u> </u>	Probable	6 (20.0)	24 (80.0)	
<u></u>	Not reported	2 (14.3)	12 (85.7)	

## **Table 3: Completion of MDV by the socio-demographic characteristics and other factors**

Had access to healthcare during the COVID-19 pandemic	Yes	3 (8.6)	32 (91.4)	0.562
	No	55 (15.2)	306 (84.8)	
	Not reported	1 (16.7)	5 (83.3)	
Perceived risk of infection with COVID-19	No risk	27 (19.0)	115 (81.0)	0.069
	At risk	32 (12.3)	228 (87.7)	
History of the household member who died of COVID-19	No	56 (15.1)	314 (84.9)	0.166
	Yes	2 (6.7)	28 (93.3)	
	Do not know	1 (50.0)	1 (50.0)	
Would recommend the COVID-19 vaccine to others	Yes	52 (13.6)	331 (86.4)	0.005
	No	7 (36.8)	12 (63.2)	

217

218

### **Factors associated with the completion of MDV at the unadjusted and adjusted analyses**

In the unadjusted analysis, participants aged 25-59 years (PR 1.22, 95% CI 1.00-1.50) and 220 221  $\geq$ 60 years (PR 1.31, 95% CI 1.07-1.61) were more likely to complete MDV compared to those 222 aged 14-24 years. Being a male compared to a female was not associated with completion of MDV (PR 1.01, 95% CI 0.93-1.10). Education levels, namely primary (PR 0.93, 95% CI 0.81-1.07), 223 secondary (PR 0.88, 95% CI 0.76-1.02), and post-secondary education (PR 0.93, 95% CI 0.78-224 1.11) showed no significant association with completion of MDV compared to no formal 225 226 education. Participants who perceived themselves as being at risk for COVID-19 (PR 1.08, 95% 227 CI 0.99-1.19) and those who would recommend the vaccine to others (PR 1.37, 95% CI 0.97-1.93) tended to have a higher likelihood of completion of MDV. 228

In the adjusted analysis, participants aged ≥60 years (aPR 1.30, 95% CI 1.05-1.60) and those who would recommend the COVID-19 vaccine to others (aPR 1.40, 95% CI 1.00-1.96) were more likely to complete MDV. We found a borderline statistically significant association between

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

- being aged 25-59 years compared to 14-24 years (aPR 1.22, 95% CI 0.99 1.50), access to
- healthcare during the COVID-19 pandemic (aPR 1.09, 95% CI 0.97 1.22), and perceived risk of
- 234 COVID-19 (aPR 1.09, 95% CI 0.99 1.19).
- 235

236

### 237 Table 4. Factors associated with the completion of MDV

		Modified Poisson Regression analysis		
		Unadjusted analysis	Adjusted analysis	
Variables	Level	PR (95% CI)	aPR (95% CI)	
Site name	Korogocho	1	1	
	Viwandani	0.99 (0.91 - 1.08)	1.02 (0.93 - 1.11)	
Age group (years)	14-24	1	1	
	25-59	1.22* (1.00-1.50)	1.22 (0.99 - 1.50)	
	≥60	1.31*** (1.07-1.61)	1.30** (1.05 - 1.60)	
Sex	Female	1	1	
	Male	1.01 (0.93 - 1.10)	1.02 (0.93 - 1.11)	
Level of education	None	1	1	
	Primary	0.93 (0.81 - 1.07)	0.98 (0.85 - 1.13)	
	Secondary	0.88* (0.76 - 1.02)	0.95 (0.82 - 1.10)	
	Post-secondary	0.93 (0.78 - 1.11)	1.01 (0.83 - 1.23)	
Ever exposed to suspected COVID-19 case	No	1	1	
	Yes	0.93 (0.79 - 1.10)	0.90 (0.76 - 1.07)	
	Probable	0.93 (0.77 - 1.11)	0.93 (0.78 - 1.11)	
	Not reported	0.99 (0.80 - 1.24)	0.98 (0.81 - 1.18)	
Had access to healthcare during the COVID-19 pandemic	No	1	1	

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

	Yes	1.08 (0.97 - 1.20)	1.09 (0.97 - 1.22)
	Not reported	0.98 (0.69 - 1.41)	1.01 (0.68 - 1.51)
Perceived risk of infection with COVID-19	No risk	1	1
	At risk	1.08 (0.99 - 1.19)	1.09 (0.99 - 1.19)
Would recommend the COVID-19 vaccine to others	No	1	1
	Yes	1.37* (0.97 - 1.93)	1.40** (1.00 - 1.96)

Note: Exponentiated coefficients are the prevalence risk ratios at a 5% significance level; 95% confidence intervals in brackets: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001; PR: Unadjusted prevalence risk ratio; aPR: Adjusted prevalence risk ratio. Analysis adjusted for the survey round.

241

#### 242 **DISCUSSION**

We assessed the factors associated with the completion of MDV in Nairobi's informal 243 settlements. Our findings indicate that 8 in every 10 individuals in the informal settlements who 244 ever received a COVID-19 vaccine completed their MDV. Completion of MDV is more likely for 245 middle-aged (25-59 years) and older adults (60+ years) individuals compared to younger 246 participants (14-24 years) and among those reporting willingness to recommend COVID-19 247 vaccination to others. Furthermore, individuals who perceived themselves at risk for COVID-19 248 249 and those who had access to health services during the pandemic tended to have a higher likelihood of completing their MDV. 250

Age has been shown in previous studies to be a significant determinant of vaccine uptake <sup>11,12</sup> and our findings align with this evidence. The high completion rate of MDV among middleaged individuals, who comprise the majority of the working population, may have been likely influenced by the COVID-19 restrictions that largely affected city employees. Across urban areas,

#### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

including Nairobi, several employers mandated COVID-19 vaccination as a requirement for 255 continued employment, especially in sectors involving close contact with others, such as 256 hospitality, transport, and retail.<sup>13,14</sup> These mandates might have incentivized middle-aged workers 257 to complete their MDV regimens in order to retain their jobs and avoid financial instability 258 259 Compared to younger persons, middle-aged and older individuals might have prioritized 260 vaccination in order to reduce the risk of transmission of SARS-COV-2 (the virus causing COVID-261 19) at the household level. Diesel and colleagues (2021) argued that older adults are more likely 262 to complete their COVID-19 vaccine regimens due to a greater awareness of the health risks associated with COVID-19.15 One study indicated that older adults prioritize vaccination due to 263 their higher perceived risk of severe outcomes associated with COVID-19.<sup>16</sup> 264

We found that participants who would recommend the COVID-19 vaccine to others are 265 more likely to complete their MDV compared to those who would not recommend the COVID-19 266 267 vaccine to others. This finding highlights the critical role of vaccine confidence in shaping health behavior. Vaccine-non-hesitant individuals often have a higher level of trust in the safety and 268 efficacy of vaccines, which motivates them to get vaccinated and advocate for others to equally 269 get vaccinated.<sup>17</sup> This positive attitude toward vaccination likely translates into greater adherence 270 to completing the full vaccine schedule since such individuals likely appreciate the benefits of 271 vaccination. Contrastingly, vaccine-hesitant individuals may harbour doubts about vaccine safety 272 or question its necessity and hence are less likely to commit to completing the multi-dose 273 regimens.<sup>17</sup> This finding emphasizes the importance of addressing vaccine hesitancy through 274 public health messaging and community engagement, particularly in settings like informal urban 275 settlements where misinformation and distrust are prevalent. 276

#### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

Individuals with a perceived risk of COVID-19 infection showed a marginally higher 277 tendency to complete their MDV. We argue that feeling at risk of COVID-19 infection, by itself, 278 may not sufficiently motivate an individual to adhere to vaccination schedules but rather other 279 factors such as the perceived benefits of full vaccination, easy access to vaccines, trust in the health 280 system, and influences from the social networks.<sup>18–20</sup> Even though some individuals might 281 282 acknowledge that they are at risk for COVID-19, they may still hesitate to get vaccinated due to 283 concerns about vaccine side effects, doubts about its effectiveness, or general mistrust of health interventions.<sup>20,21</sup> Moreover, the lack of significant findings might suggest that people often need 284 more than just a sense of risk to act. Public health theories such as the Health Belief Model 285 286 highlight that while perceived risk can increase awareness, it often takes "cues to action" to trigger a response.<sup>22</sup> These cues could include reminders from health professionals, public health 287 campaigns, or healthy public policies such as vaccine mandates. 288

There are also other important dynamics at play such as vaccine fatigue.<sup>23</sup> Some people might have been eager to get their initial dose but then become reluctant to receive subsequent doses due to misinformation or concerns after the first vaccination. This highlights that even when perceived risk is high, other competing factors may prevent people from completing their vaccination schedule.

Structural barriers such as limited access to vaccines, financial constraints, or the inability to take time off work also negatively affect people in urban slum environments regarding vaccination uptake. In urban informal settlements, basic needs such as food or income are prioritized over long-term health needs such as vaccination. Overall, public health strategies that

#### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

focus exclusively on raising awareness of the risks associated with COVID-19 may not be effectivein improving vaccine completion.

300 This study has numerous strengths and some limitations to note. The use of a modified Poisson regression analysis prevented the overestimation of associations between the independent 301 302 variables and the outcome, hence providing better estimates. The study was conducted in only two informal settlements in Nairobi so the findings may not generalize to other urban slums. Missing 303 data, particularly from participants who were unaware of the type of vaccine they had received at 304 the first shot might have led to either under or overestimation of the completion of MDV. Despite 305 these limitations, the study provides credible findings about the completion of MDV in urban 306 informal settlements where access to healthcare remains problematic and individuals are at a 307 higher risk for diseases, complications, and mortality. 308

We conclude that the completion rate for MDV is relatively high. However, to further enhance vaccination coverage, public health interventions should focus on targeted education, emphasizing the importance of completing the full vaccination schedule. These efforts should prioritize younger individuals and those displaying vaccine hesitancy, ensuring that critical gaps in coverage are addressed and sustained immunity is achieved within the population.

314

#### 315 ACKNOWLEDGEMENTS

This work is part of the African Population and Health Research Center's commitment to advancing public health research in Africa, particularly in understanding and addressing health challenges within underserved communities. We are deeply grateful to our collaborators, the

# Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

319	KEMRI Wellcome Trust Research Program and the Africa CDC, for their invaluable partnership
320	in the KEMIS project. We also wish to thank the dedicated field data collectors and the community
321	members who participated in the study, whose contributions were essential to this work. APHRC
322	had no role in the study's conceptualization, design, conduct, data analysis, or the decision to
323	submit and publish the manuscript. The contents are solely the responsibility of the authors.
324	
325	FUNDING
326	The KEMIS project was supported by funding from the Bill and Melinda Gates Foundation
327	(Ref No. C1055). The funder did not participate in the conceptualization, design, conduct, data
328	analysis, or the decision to submit and publish this manuscript.
329	
330	CONFLICT OF INTEREST
331	Authors declare no competing interests.
332	
333	AUTHOR DETAILS
334 335	Maurine Ng'oda; African Population and Health Research Center, Nairobi, Kenya; Maurinekn2012@gmail.com / mngoda@aphrc.org.
336	Jonathan Izudi; African Population and Health Research Center, Nairobi Kenya;
337	jizudi@aphrc.org.
338	Collins Otieno; African Population and Health Research Center, Nairobi, Kenya;
339	otienoc292@gmail.com.
340	Daniel Mwanga; African Population and Health Research Center, Nairobi, Kenya:
341	dmwanga@aphrc.org.

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

- Richard E. Sanya; African Population and Health Research Center, Nairobi, Kenya;
  rsanya@aphrc.org.
- 344 Abdhalah Ziraba; African Population and Health Research Center, Nairobi, Kenya;
- 345 <u>aziraba@aprc.org</u>.

346

### 347 DATA AVAILABILITY

- 348 All the data used in this manuscript are archived at
- 349 <u>https://microdataportal.aphrc.org/index.php/catalog/central</u> and can be formally requested for
- through the institutional guidelines.

351

### 352 AUTHOR DECLARATION

353 All authors have seen and approved this manuscript.

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

### REFERENCES

- 1. Kim D, Lee YJ. Vaccination strategies and transmission of COVID-19: Evidence across advanced countries. *J Health Econ.* 2022;82(January):102589. doi:10.1016/j.jhealeco.2022.102589
- 2. Our World in Data. Total COVID-19 vaccine doses administered.
- 3. Doshi RH, Nsasiirwe S, Dahlke M, et al. COVID-19 Vaccination Coverage World Health Organization African Region, 2021–2023. *MMWR Morb Mortal Wkly Rep.* 2024;73(14):307-311. doi:10.15585/mmwr.mm7314a3
- 4. Jacobs C, Musonda NC, Tembo D, et al. Gender disparities and associated factors to intention to getting a second dose of COVID-19 AstraZeneca vaccine among adult populations in selected facilities of Lusaka, Zambia. *PLOS Glob Public Heal*. 2022;2(7):e0000265. doi:10.1371/journal.pgph.0000265
- 5. Solante R, Alvarez-Moreno C, Burhan E, et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. *Expert Rev Vaccines*. 2023;22(1):1-16. doi:10.1080/14760584.2023.2143347
- 6. García-Montero C, Fraile-Martínez O, Bravo C, et al. An updated review of sars-cov-2 vaccines and the importance of effective vaccination programs in pandemic times. *Vaccines*. 2021;9(5):1-22. doi:10.3390/vaccines9050433
- 7. Crutcher M, Seidler PM. Maximizing completion of the two-dose COVID-19 vaccine series with aid from infographics. *Vaccines*. 2021;9(11). doi:10.3390/vaccines9111229
- 8. Ekezie W, Awwad S, Krauchenberg A, et al. Access to Vaccination among Disadvantaged, Isolated and Difficult-to-Reach Communities in the WHO European Region: A Systematic Review. *Vaccines*. 2022;10(7). doi:10.3390/vaccines10071038
- 9. Kagucia EW, Ziraba AK, Nyagwange J, et al. SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022. *Influenza Other Respi Viruses*. 2023;17(9):1-11. doi:10.1111/irv.13173
- 10. Beguy D, Elung'ata P, Mberu B, et al. Health & Demographic Surveillance System Profile: The Nairobi Urban Health and Demographic Surveillance System (NUHDSS). *Int J Epidemiol*. 2015;44(2):462-471. doi:10.1093/ije/dyu251
- 11. Amoah JO, Abraham SA, Adongo CA, et al. Determinants of COVID-19 vaccine uptake: evidence from a vulnerable global South setting. *BMC Res Notes*. 2024;17(1):1-7. doi:10.1186/s13104-024-06736-5
- 12. Pijpers J, van Roon A, van Roekel C, et al. Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study. *Vaccines*. 2023;11(9):1409. doi:10.3390/VACCINES11091409/S1

### Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

- 13. Lines K, Sebbanja JA, Dzimadzi S, et al. Covid-19 Vaccine Rollout: Challenges and Insights from Informal Settlements. 2022;53(3). doi:10.1177/09562478221149876
- 14. Rothstein MA, Parmet WE, Reiss DR. Employer-Mandated Vaccination for COVID-19. *Am J Public Health*. 2021;111(6):1061-1064. doi:10.2105/AJPH.2020.306166
- 15. Diesel J, Sterrett N, Dasgupta S, et al. COVID-19 Vaccination Coverage Among Adults United States, December 14, 2020–May 22, 2021. *Morb Mortal Wkly Rep.* 2021;70(25):922-927. doi:10.15585/mmwr.mm7025e1
- 16. Bhanu C, Gopal DP, Walters K, Chaudhry UAR. Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review. *PLoS Med.* 2021;18(11):1-17. doi:10.1371/journal.pmed.1003826
- Naranjo D, Kimball E, Nelson J, et al. Differences in perceptions and acceptance of COVID-19 vaccination between vaccine hesitant and non-hesitant persons. *PLoS One*. 2023;18(9 September):1-15. doi:10.1371/journal.pone.0290540
- Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. *PLoS Negl Trop Dis*. 2020;14(12):e0008961. doi:10.1371/journal.pntd.0008961
- 19. Roberts-McCarthy E, Buck PO, Smith-Ray RL, et al. Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic. *Vaccines*. 2023;41(29):4257-4266. doi:10.1016/j.vaccine.2023.03.076
- 20. Osur J, Muinga E, Carter J, Kuria S, Hussein S, Ireri EM. COVID-19 vaccine hesitancy: Vaccination intention and attitudes of community health volunteers in Kenya. *PLOS Glob Public Heal*. 2022;2(3 March):1-19. doi:10.1371/journal.pgph.0000233
- 21. Biswas MR, Alzubaidi MS, Shah U, Abd-Alrazaq AA, Shah Z. A scoping review to find out worldwide covid-19 vaccine hesitancy and its underlying determinants. *Vaccines*. 2021;9(11):1-20. doi:10.3390/vaccines9111243
- 22. Rukchart N, Hnuploy K, Eltaybani S, et al. Prevalence and determinants of COVID-19 vaccine acceptance among vulnerable populations in Thailand: An application of the health belief model. *Heliyon*. 2024;10(4):e26043. doi:10.1016/j.heliyon.2024.e26043
- 23. Stamm TA, Partheymüller J, Mosor E, et al. Determinants of COVID-19 vaccine fatigue. *Nat Med.* 2023;29(5):1164-1171. doi:10.1038/s41591-023-02282-y